BUY Dr. Reddy's Laboratories — Akshay Bhagwat, 26 Oct 2026

BUYDr. Reddy's Laboratories Limited

Dr. Reddy's Laboratories share price target & all analyst calls

byAkshay Bhagwat, JM FinancialHorizon: NA (inferred Swing (≤2wk))26 Oct 2026via ET Now (Live)

Entry₹1,311.3Inferred

Target₹1,380

Total upside +5.24%

Stop loss₹1,225-6.58% risk

CMP₹1,310.9Just now

Active-0.03%+5.27%upside left 11d left

Follow Akshay Bhagwat for new calls(23% target hit, 115 closed calls)Get alerts Watch DRREDDY for new buy/sell callsGet alerts See 5 other Swing calls on DRREDDY See 73 other Swing picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 26 Oct, 3:46 pm IST

5 supporting2 neutral3 opposing

Supports the BUY call (5)

3 advisors have active short-term BUY calls on this stock, with 1 issued in the last 14 days

Advisor consensus · adjacent horizon·26 Oct · today

7 other SEBI-registered advisors have active swing BUY calls on this stock, all issued in the last 14 days

Advisor consensus · same horizon·26 Oct · today

Dr Reddy's gets DGCI clearance for Zytorvi; Here's how company shares reacted

NewsCnbc-Tv18·21 Oct · 5d ago

Dr. Reddy's received DCGI approval for Zytorvi (toripalimab) to treat advanced esophageal squamous cell carcinoma in India.

NSE · Press Release·21 Oct · 5d ago

Dr. Reddy's Laboratories received approval from the DCGI for Zytorvi (toripalimab) in combination with chemotherapy for the treatment of advanced esophageal squamous cell carcinoma in India.

BSE · Company Update·21 Oct · 5d ago

Neutral / worth noting (2)

Dr. Reddy's Laboratories Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.

NSE · Outcome of Board Meeting·23 Oct · 2d ago

Pharma Q2 Outlook: Pricing pressure, US competition to weigh on select players

NewsEt-Markets·19 Oct · 1w ago

Weighs against the BUY call (3)

MACD below its signal line — bearish momentum

Technicals · macd·26 Oct · today

Dr Reddy’s Q2 Results: Net profit falls 36% YoY to Rs 913 crore, revenue declines marginally

NewsEt-Markets·23 Oct · 2d ago

Dr Reddy’s Q2 Results: Net profit falls as lower Lenalidomide sales hit revenue; beats estimates

NewsCnbc-Tv18·23 Oct · 2d ago

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Dr. Reddy's Laboratories

All analyst calls on Dr. Reddy's Laboratories

More from Akshay Bhagwat, JM Financial

Every call and its outcome

BUY Dr. Reddy's Laboratories Limited — Akshay Bhagwat, JM Financial

AI Assessment

Other calls on Dr. Reddy's Laboratories

More from Akshay Bhagwat, JM Financial